Common Drug Review *

Submission Status

Product: Sativex

Generic Name: delta-9-tetrahydrocannabinol/cannabidiol

Manufacturer: GW Pharma Ltd.

Submission Type: Resubmission

Date Submission Received: 2007-Aug-07 **Date NOC Issued:** 2007-Aug-01

Targeted CEDAC Meeting: 2008-Jan-23 **Priority Review Granted:** Not Requested

	Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments
1	Submission Assessment	10	2007-Aug-21	2007-Aug-14	
	Submission deemed complete			2007-Aug-14	Submission deemed complete.
2	CDR Reviewers' Reports Completed • Reviewers selected and contracted • Literature search and selection completed • Systematic review of clinical data completed • Critical appraisal of pharmacoeconomic (PE) data completed • Clinical and PE reports written • Reports edited and finalized • Reviewers' reports sent to manufacturer	45	2007-Oct-30	2007-Nov-01	Additional information requested August 17, 2007. Additional information received August 30, 2007. Additional information requested September 5, 2007. Additional information received September 7, 2007. Additional information requested September 13, 2007. Additional information requested September 25, 2007. Additional information received September 27, 2007. Additional information requested September 28, 2007. Additional information received October 12, 2007.
3	Comments from Manufacturer on Reviewers' Reports Received by CDR	7	2007-Nov-08	2007-Nov-13	Due date for Manufacturer's comments November 12, 2007. Request for extension received November 7, 2007. Extension granted, new due date for manufacturer's comments is November 13, 2007.
4	Reviewers' Reply to Manufacturer's Comments Completed	7	2007-Nov-19	2007-Nov-22	New due date for reviewers reply November 22, 2007.
5	CEDAC Brief Completed and Sent to CEDAC Members	5	2008-Jan-09	2008-Jan-09	
6	CEDAC Meeting		2008-Jan-23	2008-Jan-23	CEDAC Meeting changed from January 16, 2008 to January 23, 2008. Additional information requested January 15, 2008. Additional information received January 18, 2008.
7	CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer	5	2008-Jan-30	2008-Jan-30	
8	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation	10	2008-Feb-13	2008-Feb-13	
9 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5	2008-Feb-21	2008-Feb-20	Notice of Final Recommendation issued.
	OR				
9 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
	OR				
9 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
10	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5			

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.

*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.

Reflects updates as of Thursday noon.